Published: 2023-07-17

In-Depth Reviews

Apremilast in the Management of Generalized Granuloma Annulare: A Case Series

Jazmine Nesvik, Leslie Marshall, David Cleaver, Jonathan Cleaver, Lloyd Cleaver

Page 854-859

Original Research

Medical Education in Dermatology

Research Letters

Brief Articles

Perspectives of Vitiligo Patients: Voices from National Vitiligo Conferences

Katie O'Connell, Ronnie M Youssef, Angeli Eloise Torres, Richard H Huggins

Page 886-890

Beware of the “Blue Nevus”: A Case Report

Shivani Thacker, Mincy Chakkalakal, Zachary Goldstein, Kenneth Dale Macknet

Page 896-900

A Suspected Case of Imported Yaws in New York

Mairead Moloney, Dr. Rebeca Teplitz, Dr. Brian How, Dr. Suzanne Sirota-Rozenberg

Page 906-910

Short Communications


A Rare Case of Early Pregnancy-Associated Erythema Annulare Centrifugum in a Low-Resource Setting

Erik Jaklitsch, Alicia Mizes, Francisco Sanchez, Ana Romero, Katherin Bonilla, Alaina James

Page 939-942

SKINmages: Clinical Images in Dermatology

Vesiculobullous Erythema Migrans with Central Necrosis

Julian Stashower, Abigail Wills, Barrett Zlotoff

Page 945-946

Actinomycetoma Following Traumatic Inoculation of Nocardia Brasiliensis

McKenzie A. Dirr, Mary Dick, Alan S. Boyd, Philip B. Milam

Page 947-948

Compelling Comments

Patch-Type Granuloma Annulare with Clinical and Histological Features of Morphea: A True Overlap?

Carlie Reeves, Lauryn M Falcone, Collen J Beatty, Viktoryia Kazlouskaya, Joseph English III

Page 952-957

Atopic Dermatitis

Efficacy and Safety of Roflumilast Cream 0.15% in Adults and Children Aged ≥6 Years With Mild to Moderate Atopic Dermatitis in Two Phase 3 Trials (INTEGUMENT-1 and INTEGUMENT-2)

Eric Simpson, Lawrence Eichenfield, Melinda Gooderham, Mercedes E. Gonzalez, Adelaide Hebert, Kim Papp, Vimal H. Prajapati, David Krupa, Patrick Burnett, David Berk, Robert Higham

Page s220

Posters from FC PANP 23 Dermatology Conference®: Psoriasis

Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial

Mark Lebwohl, Linda Stein Gold, Melinda J. Gooderham, Kim A. Papp, Laura K. Ferris, David N. Adam, H. Chih-ho Hong, Leon H. Kircik, Matthew Zirwas, Patrick Burnett, Robert Higham

Page s218

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Melinda Gooderham, Lynda Spelman, Shinichi Imafuku, Marco Romanelli, Joseph F. Merola, April W. Armstrong, Elizabeth Colston, Subhashis Banerjee, Thomas Scharnitz, Andrew Blauvelt

Page s219

Skin Cancer

Acne & Rosacea

Safety of Tazarotene 0.045% Lotion and Hyperpigmentation Improvements in Black Participants With Moderate-to-Severe Acne

Fran E Cook-Bolden, MD, Linda Stein Gold, MD, Hilary Baldwin, MD, Valerie Callender, MD, Andrew F Alexis, MD, MPH, Neal Bhatia, MD, Joshua A Zeichner, MD, Emil A Tanghetti, MD, Eric Guenin, PharmD, PhD, MPH

Page s221

Impact of Age or Sex on Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Participants with Moderate-to-Severe Acne

Linda Stein Gold, MD, Leon H. Kircik, MD, William Philip Werschler, MD, Hilary Baldwin, MD, Valerie Callender, MD, Lawrence Green, MD, Neil Sadick, MD, Jeffrey L. Sugarman, MD, PhD, Zoe D Draelos, MD, Emil A Tanghetti, MD, Neal Bhatia, MD

Page s222


Seborrheic Dermatitis

Patient and Healthcare Provider Perspectives on the Disease Burden of Seborrheic Dermatitis in the United States: Results From a National Survey

Raj Chovatiya, Lakshi Aldredge, Candrice Heath, Moises Acevedo, David H. Chu, Diane Hanna, Melissa Seal, Matthew Zirwas

Page s225

Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus

Andrew Blauvelt, Zoe D. Draelos, Melinda Gooderham, Edward Lain, Angela Y. Moore, Kim A. Papp, Matthew Zirwas, David Krupa, Patrick Burnett, David R. Berk, David H. Chu

Page s226


Dermal Irritation, Sensitization, and Safety of Fixed-Dose Triple-Combination Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Healthy Participants

Zoe D. Draelos, MD, Emil A. Tanghetti, MD, Linda Stein Gold, MD, Leon H Kircik, MD, Neal Bhatia, MD, Joshua A. Zeichner, MD, Jeffrey L. Sugarman, MD, PhD

Page s227

Nail Unit Disorders

Monthly Usage of Efinaconazole 10% Solution in Two Phase 3 Randomized Trials: Is One 4-mL Bottle Enough for Proper Treatment?

Steven R Feldman, MD, PhD, Tracey C Vlahovic, DPM, Warren S Joseph, DPM, C Ralph Daniel, MD, Boni Elewski, MD, Phoebe Rich, MD, Shari R Lipner, MD, PhD

Page s228